Trade Chromadex Corp - CDXC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0266 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.9217 |
| Open | 6.2217 |
| 1-Year Change | 345.68% |
| Day's Range | 6.0217 - 6.2217 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 6.0817 | 0.0600 | 1.00% | 6.0217 | 6.2517 | 6.0017 |
| Jan 17, 2025 | 5.9317 | 0.2800 | 4.95% | 5.6517 | 6.0217 | 5.6017 |
| Jan 16, 2025 | 5.6417 | -0.1700 | -2.93% | 5.8117 | 5.8117 | 5.5517 |
| Jan 15, 2025 | 5.7517 | 0.2300 | 4.17% | 5.5217 | 5.7717 | 5.4417 |
| Jan 14, 2025 | 5.4117 | 0.1200 | 2.27% | 5.2917 | 5.4317 | 5.2017 |
| Jan 13, 2025 | 5.2317 | 0.0600 | 1.16% | 5.1717 | 5.4717 | 5.1517 |
| Jan 10, 2025 | 5.2517 | -0.0400 | -0.76% | 5.2917 | 5.4117 | 5.2417 |
| Jan 8, 2025 | 5.4417 | 0.1600 | 3.03% | 5.2817 | 5.4617 | 5.2517 |
| Jan 7, 2025 | 5.3717 | 0.0000 | 0.00% | 5.3717 | 5.3817 | 5.1517 |
| Jan 6, 2025 | 5.3617 | -0.1800 | -3.25% | 5.5417 | 5.6217 | 5.3217 |
| Jan 3, 2025 | 5.5017 | 0.0300 | 0.55% | 5.4717 | 5.6417 | 5.4317 |
| Jan 2, 2025 | 5.4617 | 0.1400 | 2.63% | 5.3217 | 5.5117 | 5.2917 |
| Dec 31, 2024 | 5.2917 | -0.1500 | -2.76% | 5.4417 | 5.4917 | 5.2417 |
| Dec 30, 2024 | 5.4417 | 0.0000 | 0.00% | 5.4417 | 5.5317 | 5.3217 |
| Dec 27, 2024 | 5.5217 | 0.0000 | 0.00% | 5.5217 | 5.6117 | 5.4117 |
| Dec 26, 2024 | 5.6017 | 0.2300 | 4.28% | 5.3717 | 5.7417 | 5.3617 |
| Dec 24, 2024 | 5.4317 | 0.1200 | 2.26% | 5.3117 | 5.4417 | 5.1917 |
| Dec 23, 2024 | 5.2817 | -0.1300 | -2.40% | 5.4117 | 5.4817 | 5.2417 |
| Dec 20, 2024 | 5.4617 | 0.1500 | 2.82% | 5.3117 | 5.5317 | 5.2217 |
| Dec 19, 2024 | 5.3917 | -0.3700 | -6.42% | 5.7617 | 5.8217 | 5.3917 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Chromadex Corp Company profile
About Chromadex Corp
ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chromadex Corp revenues increased 14% to $67.4M. Net loss increased 36% to $27.1M. Revenues reflect Consumer Products Segments increase of 20% to $56.7M, Analytical Reference Standards and Service segment increase of 12% to $3.3M. Higher net loss reflects Corporate and other segment loss increase of 19% to $36.4M, Ingredients Segments income decrease of 27% to $3.7M.
Equity composition
Common Stock $.001 Par, 08/11, 150M auth., 60,875,325 issd. Insiders & Strategic holders own 45.88%. 04/16, 1-for-3 recerse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
10900 Wilshire Blvd
Suite 600
LOS ANGELES
CALIFORNIA 90024
US
News
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
15:24, 21 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com